BioAge Labs shares have adequate space to run as the biotechnology company’s weight problems treatment is poised to acquire traction in the thriving weight management services market, according to Citigroup. The bank updated BioAge to purchase from neutral on Wednesday, doubling its 12-month rate target on the stock to $10 from $5, suggesting 89% upside from Tuesday’s close. “Provided assistance for several [obesity product] and third-party information readouts over the next ~ 12-15 months, our company believe it’s suitable to update BIOA,” Citi expert Samantha Semenkow stated in a note to customers. “We see the upcoming medical information from both BioAge and rivals as prospective stock moving drivers.” BioAge is most likely to see upside from its unique weight problems treatment, BGE-102, an extremely powerful small-molecule NLRP3 inhibitor, according to Citi. The business started a Stage I research study of the treatment last summer season. BGE-102 might be recommended by itself or in mix with an oral GLP-1 drug such as Rybelsus, a function that might increase its market penetration. “In our evaluation, BGE-102 appearance[s] appealing as a possibly separated NLRP3 inhibitor that might function as a combination alternative with oral GLP1s and/or as a monotherapy,” Semenkow composed. GLP-1 usage has actually increased substantially over the previous couple of years. In a 2024 survey, one in 8 grownups reported utilizing GLP-1 drugs, with more than 40% of diabetics aged 18 or older stating they ‘d utilized a GLP-1 item, according to non-profit research study company KFF, previously the Kaiser Household Structure. Citi’s upgrade is at chances with the agreement on Wall Street. 3 experts have a hang on BioAge shares, while one expert has actually ranked the stock underperform, LSEG information programs. BioAge’s stock iis ahead 13% on Wednesday, bringing the gain over the previous 6 months to 43%.
Related Articles
Add A Comment